Capital Advisors Wealth Management’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.3K Buy
15,000
+4,500
+43% +$9.24K ﹤0.01% 217
2025
Q4
$29.5K Buy
+10,500
New +$24.4K ﹤0.01% 217

Other funds holding CRDF

Capital Advisors Wealth Management's CRDF Position: Q1 2026 in Review

Capital Advisors Wealth Management increased its Cardiff Oncology (CRDF) stake by 43% in Q1 2026, buying an estimated $9.24K and bringing the position to 15,000 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #217.

Capital Advisors Wealth Management first reported a position in CRDF in Q4 2025 and has held it in 2 quarters since. The position peaked at $29.5K in Q4 2025. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Capital Advisors Wealth Management held 15,000 shares of Cardiff Oncology worth $24.3K as of Q1 2026.
  • Capital Advisors Wealth Management bought 4,500 Cardiff Oncology shares in Q1 2026, an estimated $9.24K.
  • Cardiff Oncology made up ﹤0.01% of Capital Advisors Wealth Management's portfolio in Q1 2026, its #217 holding.
  • Capital Advisors Wealth Management first reported a position in Cardiff Oncology in Q4 2025 and has held it in 2 quarters since.
  • Capital Advisors Wealth Management's Cardiff Oncology position peaked at $29.5K in Q4 2025.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Capital Advisors Wealth Management's 13F filing for Q1 2026, filed 8 Apr 2026.